http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101850596-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-558 |
| filingDate | 2016-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101850596-B1 |
| titleOfInvention | Method for screening therapeutic agents of hematological malignancies by interaction RE-IIBP with RNF20 |
| abstract | The present invention relates to a method of screening a therapeutic agent for hematologic cancer using RE-IIBP and RNF20 binding, and more particularly, to a method for screening a therapeutic agent for hematologic cancer comprising the step of screening a candidate drug that promotes RE-IIBP and RNF20 binding. On the other hand, the present inventors confirmed that when the degree of binding of RE-IIBP and RNF20 increases, H3K79 HMTase activity of RE-IIBP is increased and RE-IIBP-mediated MEIS1 transcription is promoted to increase blood cancer cell death. And the degree of RNF20 binding increases, it can be usefully used as a screening method for hematologic cancer treatment which can treat hematologic cancer. |
| priorityDate | 2016-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.